Roberto Nussenzveig

Heading to beautiful Sao Paulo to join an incredible lineup of speakers (>300) for #UroOncoBr26! A million thanks to #FernandoMalufMDPhD for the kind invitation - excited to see @UroDocAsh @Ecastromarcos @CaPsurvivorship @neerajaiims @PGrivasMDPhD @Prof_Nick_James @SoaresAndrey @DrAndreFay @PedroIsaacsson @MilenaTariki @bavilima @SFreedlandMD @StenioZequi @PBarataMD & others. But most excited to see my former @cityofhope research fellow @mzugman, now faculty at @hosp_einstein, gracing the stage earlier this morning!

It was a short time ago (Dec 2025) that I had the honor of meeting @batraatulonc's amazing oncology team at @aiims_newdelhi! Proud to say that we have organized a terrific meeting to follow-up on initial discussions we had around collaboration. Please join us at @cityofhope on Thursday, May 14 for a vigorous discussion around forging international collaborations with #India. Esteemed guests include @jrgralow (@ASCO CMO), @PrimoLaraMD (@SWOG Co-Chair), @Nilanchali1 (#AIIMSNewDelhi), @DrAmitJoshi_TMC (@TataMemorial), @GsrivastavaMD (@US_FDA) & @neerajaiims (@huntsmancancer). Interesting in attending? DM me!

What an outstanding lineup we have for the International #GU Summit in San Sebastián. Looking forward to great debates & discussions @drenriquegrande @Ecastromarcos @MichvdHeijden @tompowles1 @neerajaiims @g_develasco @schmidingerRCC @MRoupret @giannatempopatr @DrIacovelli

#RuchiAgarwal steals the show at posters #IKCSEU26, presenting data from @montypal CBM588 trials, supporting future microbiome modulating trials like @SWOG #BIOFRONT. Congrats!! @OncoAlert @KidneyCancer

For the 2nd year in a row, two talented #MsaouelLab post-docs @UTMDAnderson, Pankaj Chauhan & Kai Yu, co-mentored with @IamLinghua, Nizar Tannir&JJ Gao each received an @AACR scholar-in-training award for #Kidneycancer research #AACR26 honoring their dedication to #CancerResearch

Always a privilege to watch Dr. @montypal present — especially in a year with so many remarkable developments at #ASCOGU26 Proud to have learned from him up close during my time at @cityofhope, and hoping now to generate high-quality data with my skilled Brazilian colleagues.

🚨Pleased to share our new paper in @ASCO journal @JCOPO_ASCO 👉 "Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment" 👉Tumor-agnostic therapies target molecular alterations regardless of histology- transforming care for patients with rare & difficult-to-treat cancers. ⭐️Clinical integration remains inconsistent. Why? One reason👉 Absence of unified guidelines. Living guidelines are urgently needed ✅ Just-in-time evidence incorporation ✅ Streamlined biomarker-driven care ✅ Access for rare/ultrarare cancers #TumorAgnostic #PrecisionOncology #RareCancers @JCOPO_ASCO @Dr_R_Kurzrock @targetcancer @ASCO @OncoAlert @oncodaily 🔗 ascopubs.org/doi/10.1200/PO…

💫🌟Transdermal estradiol is back in the conversation in prostate cancerNEJM phase 3 (STAMPEDE-1 / PATCH) challenges a long-standing paradigm. @NEJM @OncoAlert @APCCC_Lugano 1️⃣ Efficacy: noninferior to LHRH agonists 🔵 3y MFS: 87.1% vs 85.9% (HR 0.96) 🔵 5y OS: 81.1% vs 79.2% 2️⃣ Biological effect: consistent castration 🟢 Testosterone suppression maintained in 85% (both arms) 3️⃣ Toxicity: different, not necessarily less 🟣 ↓ Hot flashes: 44% vs 89% 🔴 ↑ Gynecomastia: 85% vs 42% 💡 Interpretation This is not just “an alternative”—it reopens the discussion on how we achieve androgen deprivation.Could we move toward more patient-centered ADT, balancing metabolic, cardiovascular, and quality-of-life outcomes? nejm.org/doi/full/10.10… @urotoday @oncologytube @OncLive @DuncanGilbert11 @Silke_Gillessen @mattsydes @Prof_Nick_James @AttardLab #ProstateCancer #ADT #PrecisionOncology #OncoTwitter #GUOncology

Just in time for #APCCC26 APCCC Consensus Meeting Focuses on Real-World Prostate Cancer Management out on @urotoday urotoday.com/video-lectures… In this interview, Silke Gillessen🇨🇭 and Neeraj Agarwal🇺🇸 reflect on the 🔟th anniversary of the Advanced Prostate Cancer Consensus Conference. Prof. Gillessen highlights APCCC’s unique focus on practical clinical questions lacking level-one evidence, particularly side-effect management, distinguishing it from trial-driven meetings. New features include abstract presentations, greater patient involvement on panels, and the launch of the AACR-sponsored International Prostate Cancer Symposium, expanding translational research integration alongside clinical consensus discussions. SEE YOU IN LUGANO!! @Silke_Gillessen & @AOmlin @OncoAlert 🚨 @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @UrsulaVogl @nataliagandur

Analysis of patient-reported quality of life from the #AMPLITUDE trial. @EfstathiouEleni @MethodistHosp joins @neerajaiims @huntsmancancer to discuss the AMPLITUDE phase 3 trial, which is the first to test a PARP inhibitor in #mHSPC, showing that adding niraparib to abiraterone and ADT in patients with HRR mutations reduced the risk of radiographic progression or death while maintaining overall quality of life. Dr. Efstathiou underscores that HRR-mutated disease is biologically more aggressive—most patients have high-volume metastases—making systematic genomic testing (tumor and germline) essential to identify these men early and offer appropriately intensified, mutation-directed therapy. #WatchNow > bit.ly/4kgRx9z

Don't Miss! The #APCCC26 Consensus Meeting focuses on real-world #ProstateCancer management. @Silke_Gillessen joins @neerajaiims to discuss the upcoming 10th aniversary meeting, Apr 30th - May 2nd, shaping how we manage advanced prostate cancer in the real world and tackling everyday clinical questions without level 1 evidence—especially side effect management. Global impact continues with regional adaptations, plus new additions like abstracts, more patient voices, and the inaugural International Prostate Cancer Symposium sponsored by @AACR #WatchNow on UroToday > bit.ly/4stocLe @APCCC_Lugano

🌟Oligorecurrent HSPC: are we overinterpreting early signals? @JCO_ASCO @OncoAlert @APCCC_Lugano The ongoing discussion around the LUNAR trial reminds us of something essential: 👉 not all “oligometastatic” disease behaves the same 🔹 1. Imaging is redefining disease • PSMA-PET is identifying smaller-volume recurrence 👉 But are we changing biology… or just detecting it earlier? 🔹 2. MDT enthusiasm vs evidence • Metastasis-directed therapy is appealing • But survival impact remains uncertain 👉 Are we treating lesions… or the disease? 🔹 3. The systemic component remains key • Even in low-volume recurrence • Risk of micrometastatic disease persists 👉 Local control ≠ disease control 💡 My take: Oligorecurrence sits in a grey zone between localized and systemic disease 👉 The challenge is not whether to treat 👉 but how much and for how long 🔗 bit.ly/4m8n921 @ecancer @urotoday @UrologyTimes @MedicalwatchHQ @urologysummit #ProstateCancer #pcsm #Oligometastatic #PrecisionOncology #OncoTwitter

Prognostic tool evaluated for early treatment decisions for metastatic hormone-sensitive #ProstateCancer. @Soum_Roy_RadOnc @RadOncUH joins @neerajaiims @huntsmancancer sharing research on the NADIR prognostic model, which predicts early PSA response in #mHSPC patients receiving ADT plus ARPI. #WatchNow > bit.ly/4qm1VyL

The #KCRS2026 meeting will promise to be unique. Submit your #kidneycancer abstracts by using this link: kcrs.kidneycan.org/call-for-abstr… And new this year...PLENARIES!

Conf Highlights #GU26 from #CommunityOnc: 1. #POSEIDON: recurrent CSPC 2. #PEACE3 mCRPC 3. #BRCAAway: HRRm mCRPC 4. #KEYNOTEB15: MIBC 5. #LITESPARK022: Adj RCC 6. #LITESPARK011: RCC 2L #OncTwitter #gusm @ASCO @OncoAlert @OncUpdates 1/7

Thank you @ASCO #DailyNews for highlighting abs #676 #705 exploring RW Rx patterns and outcomes following 1L EV/pembro #bladdercancer Survival outcomes are limited. 2L after EV/pembro remains an area of unmet need ➡️ tinyurl.com/mbk6r88c @urotoday @OncoAlert @neerajaiims

@ziremozay does it again! 🙌 Presenting two high-impact projects at @ASCO #GU26 this year. ➡️ Real-world use of 1L EV/P in aUC ➡️ Real-world outcomes with Erdafitinib and prior EV Both are must-sees — swing by Posters D16 & D18 to check them out! ⭐️ @huntsmancancer

We presented exploratory analysis from pts with PR/CR on EV-302 trial #ASCOGU26. Poster Walk @Dr_Aggen 🔹 CR -30% w/ EVP vs 15% w/chemo 🔹 Median time to PR/CR w/ EVP -2.1 mo 🔹 PFS OS maintained at 24 mos PR/CR 🔹 20% pts who had CR on EVP converted from initial PR at median 4.6 mo These data reiterate that it's imp to continue Tx with dose reductions/breaks when necessary. @tompowles1 @Uromigos @CleClinicMD @OncoAlert @OncBrothers

PTEN as a prognostic marker and clinical decision tool in #mHSPC: Multidisciplinary discussion. @Daniel_J_George, Neal Shore, MD, FACS, David Morris, MD, FACS & @neerajaiims review the CAPItello-281 Phase III trial, highlighting PTEN loss as a critical prognostic marker identifying a high-risk subset of patients with metastatic hormone-sensitive #ProstateCancer. #WatchNow > bit.ly/4slFxqL

Congratulations @drmpk91. Great to see third clinical trial in last three months on optimal dosing of immune checkpoint inhibitors from @aiims_newdelhi @TataMemorial and @cmcvellore. Definitely calls for action!